XtalPi has invested in collaboration partner Metis Pharamceuticals, which is targeting disorders including endometriosis and uterine fibroids.
Metis Pharmaceuticals, a China-based drug developer leveraging artificial intelligence-driven models, has collected over RMB100m ($15.3m) in angel and pre-series A funding from investors including pharmaceutical company XtalPi, DealStreetAsia reported yesterday..
XtalPi contributed to the angel round, which was led by Sequoia Capital China and backed by Source Code Capital, Frees Fund and Forcefield Venture.
The pre-series A round was led by Lightspeed China Partners and included 5Y Capital (formerly Morningside Group) and unnamed existing investors. Investment bank China Renaissance facilitated both…
